A61K 51/0485
Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex
Official title: {Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex the radioactive metal}
A61K51/0485 (Porphyrins, texaphyrins wherein the nitrogen atoms forming the central ring system complex) appears on 104 US grants and 71 published applications in this corpus.
Search patents in A61K- Granted patents
- 104
- Published applications
- 71
- Assignees
- 60
- Inventors
- 194
- Latest grant
- 19 Nov 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 2 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 5 | 0 |
| 1995 | 9 | 0 |
| 1996 | 11 | 0 |
| 1997 | 8 | 0 |
| 1998 | 8 | 0 |
| 1999 | 7 | 0 |
| 2000 | 4 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 2 |
| 2003 | 2 | 6 |
| 2004 | 3 | 4 |
| 2005 | 2 | 3 |
| 2006 | 6 | 2 |
| 2007 | 1 | 2 |
| 2008 | 0 | 3 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 4 | 1 |
| 2013 | 2 | 2 |
| 2014 | 3 | 2 |
| 2015 | 0 | 3 |
| 2016 | 2 | 1 |
| 2017 | 2 | 1 |
| 2018 | 0 | 2 |
| 2019 | 0 | 4 |
| 2020 | 2 | 5 |
| 2021 | 1 | 3 |
| 2022 | 3 | 4 |
| 2023 | 1 | 6 |
| 2024 | 4 | 3 |
| 2025 | 0 | 7 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer19 Nov 2024US 12,144,874 B2On Target Laboratories, LLC
- Imaging and radiotherapeutics agents targeting fibroblast-activation protein-α (FAP-α)15 Oct 2024US 12,115,233 B2The Johns Hopkins University
- PSMA targeted compounds and uses thereof4 Jun 2024US 11,998,620 B2Case Western Reserve University
- Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (FAP-alpha)26 Mar 2024US 11,938,201 B2The Johns Hopkins University
- Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies25 Apr 2023US 11,633,506 B2Wisconsin Alumni Research Foundation
- Methods for reducing and/or preventing de-chelation of a chelated radioisotope24 Sep 2026US 2026/0284236 A1Curadel Surgical Innovations, Inc.
- Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies11 Jun 2026US 2026/0158176 A1Wisconsin Alumni Research Foundation
- Psma targeted conjugate compounds and uses thereof30 Oct 2025US 2025/0332265 A1
- Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer14 Aug 2025US 2025/0255991 A1On Target Laboratories, LLC
- Imaging and radiotherapeutics agents targeting fibroblast-activation protein-alpha (fap-alpha)24 Jul 2025US 2025/0235565 A1The Johns Hopkins University
Most cited
By later US patents
- Method of expanded porphyrin-oligonucleotide conjugate synthesis325US 5,565,552 ABoard of Regents, Univ. of Texas Sys. · 1996
- Texaphyrin-oligonucleotide conjugates308US 5,587,371 ABoard of Trustees, Univ. of TX Sys. · 1996
- Balloon dilation catheter256US 5,312,430 A1994
- Texaphyrin metal complexes having improved functionalization254US 5,599,923 ABoard of Regents, University of TX · 1997
- Texaphyrin compounds having improved functionalization233US 5,599,928 ABoard of Regents, The University of Texas System · 1997